General Information of Drug (ID: DMRUIX3)

Drug Name
GP515 Drug Info
Synonyms
1H-Pyrazolo(3,4-d)pyrimidin-4-amine, 1-(5-amino-5-deoxy-beta-D-ribofuranosyl)-3-bromo-; GP 1-515; CHEMBL356141; 144928-48-3; GP-515; Adenosine kinase inhibitor GP515; GP-1-515; SCHEMBL2053010; AC1L31E2; DTXSID30162847; BDBM50134744; 1-(5-Amino-5-deoxy-beta-D-ribofuranosyl)-3-bromo-1H-pyrazolo(3,4-d)pyrimidin-4-amine; 4-Amino-1-(5-amino-5-deoxy-1-beta-D-ribofuranosyl)-3-bromopyrazolo(3,4-d)pyrimidine; (2R,3R,4S,5R)-2-(4-amino-3-bromopyrazolo[3,4-d]pyrimidin-1-yl)-5-(aminomethyl)oxolane-3,4-diol; 19-nor-10-azasteroid skeleton
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
132663
CAS Number
CAS 144928-48-3
TTD Drug ID
DMRUIX3

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
FR-146687 DMGO45I Prostate disease GA91 Phase 2 [3]
MK-386 DM48ELZ Acne vulgaris ED80 Discontinued in Phase 2 [4]
AS-601811 DMINF80 Acne vulgaris ED80 Discontinued in Phase 1 [5]
Bexlosteride DMH7YD4 N. A. N. A. Terminated [4]
2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol DMRVYKQ Discovery agent N.A. Investigative [6]
4-[4-benzyloxy)benzoyl]benzoic acid DMQ9IN4 Discovery agent N.A. Investigative [7]
4-[4-(benzhydryloxy)benzoyl]benzoic acid DM8MVE9 Discovery agent N.A. Investigative [7]
(3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid DMX5CY3 Discovery agent N.A. Investigative [7]
(3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid DMPHM23 Discovery agent N.A. Investigative [7]
{4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid DMX53OY Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Finasteride DMWV3TZ Baldness, male pattern Approved [8]
2,3,5,6-Tetrafluoro-4-pentafluorophenylazo-phenol DMRVYKQ Discovery agent N.A. Investigative [6]
4-[4-benzyloxy)benzoyl]benzoic acid DMQ9IN4 Discovery agent N.A. Investigative [7]
4-[4-(benzhydryloxy)benzoyl]benzoic acid DM8MVE9 Discovery agent N.A. Investigative [7]
(3-methyl-4-(4-phenoxybenzoyl)phenyl)acetic acid DMX5CY3 Discovery agent N.A. Investigative [7]
(3-fluoro-4-(4-phenoxybenzoyl)phenyl)acetic acid DMPHM23 Discovery agent N.A. Investigative [7]
{4-[4-(4-bromophenoxy)benzoyl]phenyl}acetic acid DMX53OY Discovery agent N.A. Investigative [7]
(E)-3-(4-(4-phenoxybenzoyl)phenyl)acrylic acid DMOWGT3 Discovery agent N.A. Investigative [7]
4,4'-dihydroxyoctafluoroazobenzene DM1ONBT Discovery agent N.A. Investigative [6]
4-(4-phenoxybenzoyl)benzoic acid DMOHB6U Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Adenosine kinase (ADK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
GP-3269 DM035LO Convulsion 8A68.Z Phase 1 [9]
ABT-702 DMYJMV9 Pain MG30-MG3Z Terminated [10]
GP-683 DMPODL9 Pain MG30-MG3Z Terminated [11]
A-134974 DMRWDX5 Epilepsy 8A60-8A68 Terminated [12]
5'-iodotubercidin DML5ZEJ Discovery agent N.A. Investigative [13]
MB-03966 DM9KLQC Epileptic seizures 8A61-8A6Z Investigative [14]
5-iodo,5'-deoxytubercidin DMVT2LW Discovery agent N.A. Investigative [15]
6-Benzylthioinosine DMNXGZP Discovery agent N.A. Investigative [16]
Iodotubercidin DMQMH6S Discovery agent N.A. Investigative [17]
⏷ Show the Full List of 9 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adenosine kinase (ADK) TTL732K ADK_HUMAN Inhibitor [2]
Steroid 5-alpha-reductase 1 (SRD5A1) TTTU72V S5A1_HUMAN Inhibitor [1]
Steroid 5-alpha-reductase 2 (SRD5A2) TTT02K8 S5A2_HUMAN Inhibitor [1]

References

1 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. J Med Chem. 1997 Mar 28;40(7):1112-29.
2 Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther. 2001 Jan;296(1):99-105.
3 Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses. Br J Clin Pharmacol. 2002 Sep;54(3):283-94.
4 Synthesis of 8-chloro-benzo[c]quinolizin-3-ones as potent and selective inhibitors of human steroid 5alpha-reductase 1. Bioorg Med Chem Lett. 2000 Feb 21;10(4):353-6.
5 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013228)
6 Hydroxyperfluoroazobenzenes: novel inhibitors of enzymes of androgen biosynthesis. J Med Chem. 1990 Sep;33(9):2452-5.
7 Novel 5alpha-reductase inhibitors: synthesis, structure-activity studies, and pharmacokinetic profile of phenoxybenzoylphenyl acetic acids. J Med Chem. 2006 Jan 26;49(2):748-59.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Adenosine kinase inhibitors. 6. Synthesis, water solubility, and antinociceptive activity of 5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidines substituted at C4 with glycinamides andrelated compounds. J Med Chem. 2005 Dec 1;48(24):7808-20.
10 ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013 Jul 30;93(2-3):78-88.
11 The effect of GP683, an adenosine kinase inhibitor, on the desflurane anesthetic requirement in dogs. Anesth Analg. 1997 Sep;85(3):675-80.
12 Effects of A-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action. J Pharmacol Exp Ther. 2001Feb;296(2):501-9.
13 Inhibition of adenosine kinase attenuates interleukin-1- and lipopolysaccharide-induced alterations in articular cartilage metabolism. Osteoarthritis Cartilage. 2005 Mar;13(3):250-7.
14 Engineered Adenosine-Releasing Cells for Epilepsy Therapy: Human Mesenchymal Stem Cells and Human Embryonic Stem Cells. Neurotherapeutics. 2009 April; 6(2): 278-283.
15 Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes. J Med Chem. 2006 Nov 16;49(23):6726-31.
16 Structure-activity relationships of carbocyclic 6-benzylthioinosine analogues as subversive substrates of Toxoplasma gondii adenosine kinase. Bioorg Med Chem. 2010 May 15;18(10):3403-12.
17 Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.